NL-OMON30203尚未招募不适用
Does atorvastatin reduce ischemia-reperfusion injury in humans in-vivo? - Ator01
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Age 18-50 years
- •-Informed consent
- •-Physical able to perform ischemic exercise
排除标准
- •-History of any cardiovascular disease
- •-Hypertension (in supine position: systole > 140 mmHg, diastole > 90 mmHg)
- •-Diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
- •-Hyperlipidaemia (random total cholesterol > 6 mmol/l)
- •-Alanine-Amino-Transferase (ALAT) >90 U/L (more than twice the upper level of the normal range)
- •-Creatinine Kinase (CK) >340 U/L (more than twice the upper level of the normal range)
- •-Drug abuse
- •-Concomitant chronic use of medication
- •-Administration of radioactivity in research setting during the last 5 years
- •-Participation to any drug-investigation during the previous 60 days as checked with VIP check according to CRCN standard procedures
研究者
相似试验
进行中（未招募）
1 期
Does atorvastatin reduce ischemia-reperfusion injury in humans in-vivo? - atorEUCTR2006-006706-29-NLMCN department Pharm-Tox20
已完成
2 期
Rosuvastatin and Ischemia ReperfusionIschemiaNCT00315510Radboud University Medical Center20
已完成
4 期
Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?Ischemia Reperfusion InjuryCardiovascular DiseaseNCT00441597Radboud University Medical Center30
尚未招募
3 期
The effect of atorvastatin on Covid 19IRCT20210426051090N1Shahre-kord University of Medical Sciences80
已完成
3 期
Impact of ATOrvastatin REload on the Prevention of Contrast-INduced Nephropathy in patients on Chronic Statin Therapy: A prospective randomized trial (ATORE-CIN)renal diseasesPACTR202110707328144hedi chaker hospital102